Product替尔泊肽 / Tirzepatide
Mounjaro
A dual-target GLP-1/GIP receptor agonist developed by Eli Lilly, with tirzepatide as its active ingredient. It is indicated for the treatment of type 2 diabetes and obesity, and works by simultaneously activating both GLP-1 and GIP intestinal hormone receptors.
Timeline (last 90 days)
Sep 25
Mounjaro (tirzepatide) simultaneously agonizes both GLP-1 and GIP receptors, and GIP receptor agonism may help reduce nausea side effects.
Unverified50%